# Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC

> **NCT04211090** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 45 (actual)

## Conditions studied

- Non-squamous Non-small-cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04211090
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211090, "Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04211090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*